Antimalarial benzoheterocyclic 4-aminoquinolines: Structure–activity relationship, in vivo evaluation, mechanistic and bioactivation studies
作者:Dennis S.B. Ongarora、Natasha Strydom、Kathryn Wicht、Mathew Njoroge、Lubbe Wiesner、Timothy J. Egan、Sergio Wittlin、Ulrik Jurva、Collen M. Masimirembwa、Kelly Chibale
DOI:10.1016/j.bmc.2015.07.051
日期:2015.9
Plasmodium falciparum. Structure–activity relationship studies led to the identification of highly promising analogues, the most potent of which had IC50s in the nanomolar range against both strains. The compounds further demonstrated good in vitro microsomal metabolic stability while those subjected to in vivo pharmacokinetic studies had desirable pharmacokinetic profiles. In vivo antimalarial efficacy in Plasmodium
合成了设计用于避免毒性反应性代谢产物形成的一类新的氨二喹类苯并杂环类似物,并评估了其对疟疾寄生虫恶性疟原虫的K1(耐多药)和NF54(敏感)菌株的抗疟原虫活性。结构-活性关系研究导致鉴定出高度有前途的类似物,其中最有效的类似物对两种菌株的IC 50都在纳摩尔范围内。该化合物进一步显示出良好的体外微粒体代谢稳定性,而那些进行了体内药代动力学研究的化合物则具有理想的药代动力学特征。伯氏疟原虫的体内抗疟药功效对感染的小鼠的四种化合物进行了评估,口服给药后所有化合物均显示出良好的活性。特别是,化合物19以4×10 mg / kg的低倍剂量完全治愈了治疗的小鼠。机理和生物激活研究表明,分别抑制了血红素的形成和形成醌-亚胺反应性代谢物的可能性低。